A Multicentric Randomized Phase II Trial Evaluating Dual Targeting of EGFR Using the Combination of Cetuximab and Afatinib Versus Cetuximab Alone in Patients With Chemotherapy Refractory wtKRAS Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 15 May 2018
Price : $35 *
At a glance
- Drugs Afatinib (Primary) ; Cetuximab
- Indications Colorectal cancer
- Focus Therapeutic Use
- 06 May 2018 Status changed from active, no longer recruiting to completed.
- 17 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 16 Sep 2013 New trial record